As of June 2018, a number of large Russian pharmaceutical wholesalers have experienced a significant revenue and market share decrease. The top three players in the rating are still the same, but the difference between the companies has already approached the boundaries of a statistical error, so the change of the leaders is a matter of time, which does not necessarily mean that the first and second places should switch spots.

Between January and July 2018, Russia produced 186.5 bln RUB worth of pharmaceutical drugs (dispatch prices, VAT included), which is in monetary terms 2.5% higher than that of the same period of 2017. In physical terms, the dynamics are still negative, -10.4%. Over the period, Russia produced around 2.29 bln units of pharmaceuticals.

Between January and June 2018, Russia imported 30.2 bln RUB worth of veterinary products (free circulation prices), among which 16.7 bln RUB of feed supplements (+10% in monetary terms), 12.5 bln RUB of veterinary drugs (+13.6%), and 1 bln RUB of veterinary APIs (+23.6%.)

Between January and July 2018, Russia imported 6.5 bln RUB worth of pharmaceutical drugs produced in the EEU countries (wholesale prices, VAT included), which is in monetary terms 7% higher than that of the same period of 2017. In physical terms, the dynamics are still negative, -0.6%, as Russia imported around 119.7 mln units of pharmaceuticals.

Between January and June 2018, Russia imported 46.3 bln RUB worth of APIs (free circulation prices, VAT included), which is in monetary terms 30.3% higher than that of the same period of 2017. In physical terms, the dynamics are -4.5%, which is true for the import of both pharmacopoeial and technical APIs. Since January 208, Russia has imported 5.4 tons of APIs.

Between January and June 2018, Russia imported 244.3 bln RUB worth of ready-made drugs (free circulation prices), which is in monetary terms 2% higher than that of the same period of 2017, and 52 bln RUB worth of in-bull drugs, which is in monetary terms 5% higher than that of the same period of 2017.

While Russia is still new to pharmaceutical export and the export of ready-made drugs hardly amounted to 22 bln RUB in 2017 (customs duties included, EAEU countries excluded), the API export in 2017 amounted to only 1.2 bln RUB. In a number of cases, it is not exactly export, rather return of import.